Exclusive Speaker Interview with Achim Kless, Pain Genetics Lead from Eli Lilly & Company
SMi Group Reports Achim Kless, Pain Genetics Lead from Eli Lilly & Company gives an exclusive interview ahead of SMi’s 21st Annual Pain Therapeutics Conference
LONDON, LONDON, UNITED KINGDOM, April 9, 2021 /EINPresswire.com/ -- Ahead of the 21st Annual Pain Therapeutics Conference, SMi Group had the pleasure of catching up with Achim Kless, pain genetics lead, Eli Lilly and Co to find out about Achim’s work, vital topics being addressed in his presentation, thoughts on the most innovative therapy and on how the pain industry is responding to the opioid crisis and what the biggest growth area will be in 2021. The conference will convene on the 10th and 11th May 2021.